Early clinical results with the Tendyne transcatheter mitral valve replacement system

Jared P. Beller, Jason H Rogers, Vinod H. Thourani, Gorav Ailawadi

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. The Tendyne system (Tendyne Holdings, LLC, a subsidiary of Abbott Vascular, Roseville, Minnesota) is a fully repositionable and retrievable, transapical transcatheter mitral valve replacement platform. The results of the early feasibility studies in the U.S. are highly encouraging and a pivotal randomized trial is underway. The Tendyne transcatheter mitral valve replacement valve may prove to be a safe, less invasive approach to treatment of mitral valve disease.

Original languageEnglish (US)
Pages (from-to)776-779
Number of pages4
JournalAnnals of Cardiothoracic Surgery
Issue number6
StatePublished - Nov 1 2018


  • Mitral valve regurgitation
  • Tendyne
  • Transcatheter mitral valve replacement (TMVR)

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Early clinical results with the Tendyne transcatheter mitral valve replacement system'. Together they form a unique fingerprint.

Cite this